In the field of cardiometabolic diseases and diabetes, the experts are: Pr Nikolaus Marx, Professor of Medicine and Cardiology at the University of Ulm (Germany), specializes in cardiovascular disease. He received the G.B Morgagni award in 2004.
Pr Markus Stoffel, Professor of Molecular Biology at the EHT in Zurich (Switzerland), specializes in biological and genetic mechanisms that regulate the homeostasis of glucose and lipids.
Pr Arnold von Eckardstein, Professor of Medicine and President of the Institute of Clinical Chemistry of the Zurich University Hospital, is an expert in metabolism of HDL and atherosclerosis.
Pr Gerald F. Watts, Professor of Medicine and Pharmacology at the University of Western Australia (Crawley), specializes in lipid disorders and the metabolic syndrome.
“It’s a great privilege for us to have assembled such a distinguished group of leading experts in our Scientific Advisory Board. Our activities in metabolic and cardiovascular fields and especially our programs in diabetes will greatly benefit from their expertise” stated Professor Bart Staels, President of the Scientific Advisory Board and cofounder of GENFIT.
Jean-François Mouney, Chairman and Chief Executive Officer and cofounder of GENFIT, added “We are honored to have these renowned international experts joining our Scientific Advisory Board. Their decision to join our team is recognition of our therapeutic development strategy on an international level and reinforces our scientific approaches to prevent and fight today’s major diseases. Our Scientific Advisory Board will be extended in the coming weeks with experts in neurodegenerative diseases.”
Supplementary biographical information:
Nikolaus Marx is Professor of Medicine and Cardiology at the University of Ulm (Germany) and graduated from the Universities of Mainz, Geneva and Düsseldorf. He is a member of several organizations including the European Society of Cardiology, the American Heart Association (AHA) and the European Association for the Study of Diabetes. In 2004, he received the G.B Morgagni award.
Markus Stoffel is Professor of Molecular Biology at the EHT (Zurich) and graduated from the medical universities of Cambridge (United Kingdom) and Bonn (Germany). He directed the Laboratory of Metabolic Diseases at Rockefeller University (New York). His research focuses on the molecular and genetic mechanisms that regulate glucose and lipid homeostasis which are dysregulated in complex human diseases such as type 2 diabetes. He has received various awards, including prizes from the American Diabetes Association (1997, 2004). He was elected in 2006 as a member of the German Academy of Sciences Leopoldina.
Arnold von Eckardstein is Professor of Medicine and President of the Institute of Clinical Chemistry of the Zurich University Hospital. His research focus includes the metabolism of HDL and atherosclerosis. He is a member of the Executive Committee of the International Task Force for Prevention of Coronary Heart Disease.
Gerald F. Watts graduated from the University of London. He is Professor of Medicine and Pharmacology at the University of Western Australia (Crawley), and is leading the NHMRC Clinical Center for Excellence and Metabolic Research Center at the Royal Perth Hospital. His research focuses on lipid disorders and the metabolic syndrome. He is also author of over 300 scientific publications and articles.
About GENFIT:
A biopharmaceutical company, GENFIT studies the regulation and function of genes implicated in many of the most widespread diseases. GENFIT’s scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT’s programs, conducted in partnership with pharmaceutical companies which include SANOFI-AVENTIS, SOLVAY GROUP, PIERRE FABRE, MERCK AG, and SERVIER, treat the most prevalent metabolic diseases. GENFIT’s development of proprietary drugs focuses on early diagnosis, prevention and treatment of micro and macrovascular diseases in pre-diabetes and diabetes. GENFIT is also committed in research programmes in specific neurodegenerative diseases. GENFIT possesses a rich and diversified pipeline of drug candidates at different stages of development – development carried out by GENFIT alone or in partnership. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and another compound in partnership with SANOFI-AVENTIS (AVE0897) is now completing Phase I. With facilities in Lille, France, and Cambridge, MA (USA), the company has over 130 employees on staff, including over 100 scientists. GENFIT is a public company listed on the Alternext by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111).www.genfit.com
